Mulberrofuran G

Mulberrofuran G is a NOX inhibitor (IC₅₀: 6.9 μM) and tyrosinase inhibitor. Mulberrofuran G exhibits anti-inflammatory, antioxidant, antiviral, antitumor, and neuroprotective effects. Mulberrofuran G can be used in the research of tumors, nervous system diseases, and other conditions^{[1][2][3][4][5]}. In Vitro:Mulberrofuran G (0.89-909.42 μM) inhibits HBV DNA replication in HepG 2.2.15 cells with an IC₅₀ of 3.99 μM, and exhibits cytotoxicity to HepG 2.2.15 cells with a CC₅₀ of 8.04 μM^[1].
Mulberrofuran G (1-100 μM; 24 h) significantly suppresses cell proliferation, migration, and invasion in A549 and NCI-H226 cells, with the mechanism involving the inhibition of the JAK2/STAT3 pathway^[2].
Mulberrofuran G (0-3 μM; 24 h) potently inhibits the infection of SARS-CoV-2 (βCoV/Korea/KCDC03/2020) in Vero cells, with an IC₅₀ of 1.55 μM^[3].
Mulberrofuran G (0.016-2 μM; 4-40 h) enhances cell viability, suppresses ROS production and apoptotic signals, and alleviates ER stress in oxygen-glucose deprivation/reoxygenation-treated SH-SY5Y cells. The mechanism is associated with the inhibition of NOX4^[4]. In Vivo:Mulberrofuran G (0.2-5 mg/kg; intraperitoneal injection; single dose; 30 min before operation) exerts a protective effect in a rat model of middle cerebral artery occlusion/reperfusion^[4].